Ubs Group Ag Blueprint Medicines Corp Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Ubs Group Ag holds 117,556 shares of BPMC stock, worth $10.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

117,556

Previous 84,623 38.92%

Holding current value

$10.6 Million

Previous $9.12 Million 19.18%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $2.77 Million - $3.97 Million	32,933 Added 38.92%	117,556 $10.9 Million
Q2 2024 Aug 13, 2024	SELL	$85.18 - $108.78 $3.48 Million - $4.44 Million	-40,812 Reduced 32.54%	84,623 $9.12 Million
Q1 2024 May 13, 2024	SELL	$73.17 - $99.79 $80,706 - $110,068	-1,103 Reduced 0.87%	125,435 $11.9 Million
Q4 2023 Feb 09, 2024	BUY	$43.96 - $92.84 $2.7 Million - $5.71 Million	61,486 Added 94.52%	126,538 $11.7 Million
Q3 2023 Nov 09, 2023	SELL	$46.9 - $66.0 $783,886 - $1.1 Million	-16,714 Reduced 20.44%	65,052 $3.27 Million
Q2 2023 Aug 11, 2023	SELL	$42.2 - $66.37 $122,675 - $192,937	-2,907 Reduced 3.43%	81,766 $5.17 Million
Q1 2023 May 12, 2023	SELL	$37.97 - $50.0 $1.91 Million - $2.51 Million	-50,185 Reduced 37.21%	84,673 $3.81 Million
Q4 2022 Feb 08, 2023	BUY	$41.06 - $66.48 $5.15 Million - $8.34 Million	125,458 Added 1334.66%	134,858 $5.91 Million
Q3 2022 Nov 10, 2022	SELL	$49.93 - $77.7 $1.19 Million - $1.85 Million	-23,848 Reduced 71.73%	9,400 $619,000
Q2 2022 Aug 10, 2022	SELL	$45.23 - $70.15 $680,937 - $1.06 Million	-15,055 Reduced 31.17%	33,248 $1.68 Million
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $866,573 - $1.76 Million	-16,018 Reduced 24.9%	48,303 $3.09 Million
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $1.09 Million - $1.35 Million	11,617 Added 22.04%	64,321 $6.89 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $2.6 Million - $3.51 Million	32,101 Added 155.81%	52,704 $5.42 Million
Q2 2021 Aug 13, 2021	SELL	$82.78 - $101.0 $3.68 Million - $4.5 Million	-44,510 Reduced 68.36%	20,603 $1.81 Million
Q1 2021 May 12, 2021	BUY	$90.71 - $108.28 $4.3 Million - $5.14 Million	47,436 Added 268.35%	65,113 $6.33 Million
Q4 2020 Feb 11, 2021	BUY	$92.08 - $124.48 $1.12 Million - $1.52 Million	12,178 Added 221.46%	17,677 $1.98 Million
Q3 2020 Nov 12, 2020	SELL	$66.45 - $92.7 $216,228 - $301,645	-3,254 Reduced 37.18%	5,499 $510,000
Q2 2020 Jul 31, 2020	BUY	$57.09 - $79.27 $267,580 - $371,538	4,687 Added 115.27%	8,753 $683,000
Q1 2020 May 01, 2020	SELL	$48.11 - $82.22 $976,633 - $1.67 Million	-20,300 Reduced 83.31%	4,066 $238,000
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $2.37 Million - $2.94 Million	-35,564 Reduced 59.34%	24,366 $1.95 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $4.33 Million - $6.02 Million	59,370 Added 10601.79%	59,930 $4.4 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $16,546 - $22,005	225 Added 67.16%	560 $53,000
Q1 2019 May 14, 2019	SELL	$48.7 - $86.6 $1.65 Million - $2.93 Million	-33,799 Reduced 99.02%	335 $27,000
Q4 2018 Feb 14, 2019	BUY	$45.57 - $74.26 $514,394 - $838,246	11,288 Added 49.41%	34,134 $1.84 Million
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $1.32 Million - $1.76 Million	22,456 Added 5757.95%	22,846 $1.78 Million
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $3.44 Million - $5.71 Million	-56,428 Reduced 99.31%	390 $25,000
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $2.91 Million - $4.09 Million	39,774 Added 233.36%	56,818 $5.21 Million
Q4 2017 Feb 14, 2018	SELL	$62.91 - $88.32 $1.03 Million - $1.45 Million	-16,391 Reduced 49.02%	17,044 $1.29 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $448,867 - $738,083	10,594 Added 46.38%	33,435 $2.33 Million
Q2 2017 Aug 14, 2017	BUY	N/A	15,513 Added 211.69%	22,841 $1.16 Million
Q1 2017 Nov 14, 2017	BUY	N/A	7,328	7,328 $293,000

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account